Regeneration and repair of neural tissue using postpartum-derived cells
First Claim
Patent Images
1. An isolated postpartum-derived cell comprising a cell derived from human placental or umbilical cord tissue substantially free of blood, wherein the cell is capable of self-renewal and expansion in culture and has the potential to differentiate into a cell of a neural phenotype;
- wherein the cell requires L-valine for growth and is capable of growth in at least about 5% oxygen;
wherein the cell further comprises at least one of the following characteristics;
a) potential for at least about 40 doublings in culture;
b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyomithine, vitronectin, or fibronectin;
c) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin;
d) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
e) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
f) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of a gene encoding;
interleukin 8;
reticulon 1;
chemokine (C—
X—
C motif) ligand 1 (melonoma growth stimulating activity, alpha);
chemokine (C—
X—
C motif) ligand 6 (granulocyte chemotactic protein
2);
chemokine (C—
X—
C motif) ligand 3;
tumor necrosis factor, alpha-induced protein 3;
C-type lectin superfamily member 2;
Wilms tumor 1;
aldehyde dehydrogenase 1 family member A2;
renin;
oxidized low density lipoprotein receptor 1;
Homo sapiens clone IMAGE;
4179671;
protein kinase C zeta;
hypothetical protein DKFZp564F013;
downregulated in ovarian cancer 1; and
Homo sapiens gene from clone DKFZp547k1113. g) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is reduced for at least one of a gene encoding;
short stature homeobox 2;
heat shock 27 kDa protein 2;
chemokine (C—
X—
C motif) ligand 12 (stromal cell-derived factor
1);
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome);
Homo sapiens mRNA;
cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeo box 2 (growth arrest-specific homeo box);
sine oculis homeobox homolog 1 (Drosophila);
crystallin, alpha B;
disheveled associated activator of morphogenesis 2;
DKFZP586B2420 protein;
similar to neuralin 1;
tetranectin (plasminogen binding protein);
src homology three (SH3) and cysteine rich domain;
cholesterol 25-hydroxylase;
runt-related transcription factor 3;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer;
frizzled homolog 7 (Drosophila);
hypothetical gene BC008967;
collagen, type VIII, alpha 1;
tenascin C (hexabrachion);
iroquois homeobox protein 5;
hephaestin;
integrin, beta 8;
synaptic vesicle glycoprotein 2;
neuroblastoma, suppression of tumorigenicity 1;
insulin-like growth factor binding protein 2, 36 kDa;
Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, beta 7;
transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2 (Drosophila);
KIAA1034 protein;
vesicle-associated membrane protein 5 (myobrevin);
EGF-containing fibulin-like extracellular matrix protein 1;
early growth response 3;
distal-less homeo box 5;
hypothetical protein FLJ20373;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan;
transcriptional co-activator with PDZ-binding motif (TAZ);
fibronectin 1;
proenkephalin;
integrin, beta-like 1 (with EGF-like repeat domains);
Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422;
EphA3;
KIAA0367 protein;
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
hypothetical protein FLJ14054;
Homo sapiens mRNA;
cDNA DKFZp564B222 (from clone DKFZp564B222);
BCL2/adenovirus E1B 19 kDa interacting protein 3-like;
AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
similar to neuralin 1;
B cell translocation gene 1;
hypothetical protein FLJ23191; and
DKFZp586L151;
h) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and
i) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIPlb, 1309, MDC, and VEGF, as detected by ELISA.
10 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.
-
Citations
49 Claims
-
1. An isolated postpartum-derived cell comprising a cell derived from human placental or umbilical cord tissue substantially free of blood, wherein the cell is capable of self-renewal and expansion in culture and has the potential to differentiate into a cell of a neural phenotype;
- wherein the cell requires L-valine for growth and is capable of growth in at least about 5% oxygen;
wherein the cell further comprises at least one of the following characteristics;
a) potential for at least about 40 doublings in culture;
b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyomithine, vitronectin, or fibronectin;
c) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin;
d) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
e) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
f) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of a gene encoding;
interleukin 8;
reticulon 1;
chemokine (C—
X—
C motif) ligand 1 (melonoma growth stimulating activity, alpha);
chemokine (C—
X—
C motif) ligand 6 (granulocyte chemotactic protein
2);
chemokine (C—
X—
C motif) ligand 3;
tumor necrosis factor, alpha-induced protein 3;
C-type lectin superfamily member 2;
Wilms tumor 1;
aldehyde dehydrogenase 1 family member A2;
renin;
oxidized low density lipoprotein receptor 1;
Homo sapiens clone IMAGE;
4179671;
protein kinase C zeta;
hypothetical protein DKFZp564F013;
downregulated in ovarian cancer 1; and
Homo sapiens gene from clone DKFZp547k1113.g) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is reduced for at least one of a gene encoding;
short stature homeobox 2;
heat shock 27 kDa protein 2;
chemokine (C—
X—
C motif) ligand 12 (stromal cell-derived factor
1);
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome);
Homo sapiens mRNA;
cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeo box 2 (growth arrest-specific homeo box);
sine oculis homeobox homolog 1 (Drosophila);
crystallin, alpha B;
disheveled associated activator of morphogenesis 2;
DKFZP586B2420 protein;
similar to neuralin 1;
tetranectin (plasminogen binding protein);
src homology three (SH3) and cysteine rich domain;
cholesterol 25-hydroxylase;
runt-related transcription factor 3;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer;
frizzled homolog 7 (Drosophila);
hypothetical gene BC008967;
collagen, type VIII, alpha 1;
tenascin C (hexabrachion);
iroquois homeobox protein 5;
hephaestin;
integrin, beta 8;
synaptic vesicle glycoprotein 2;
neuroblastoma, suppression of tumorigenicity 1;
insulin-like growth factor binding protein 2, 36 kDa;
Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, beta 7;
transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2 (Drosophila);
KIAA1034 protein;
vesicle-associated membrane protein 5 (myobrevin);
EGF-containing fibulin-like extracellular matrix protein 1;
early growth response 3;
distal-less homeo box 5;
hypothetical protein FLJ20373;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan;
transcriptional co-activator with PDZ-binding motif (TAZ);
fibronectin 1;
proenkephalin;
integrin, beta-like 1 (with EGF-like repeat domains);
Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422;
EphA3;
KIAA0367 protein;
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
hypothetical protein FLJ14054;
Homo sapiens mRNA;
cDNA DKFZp564B222 (from clone DKFZp564B222);
BCL2/adenovirus E1B 19 kDa interacting protein 3-like;
AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
similar to neuralin 1;
B cell translocation gene 1;
hypothetical protein FLJ23191; and
DKFZp586L151;
h) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and
i) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIPlb, 1309, MDC, and VEGF, as detected by ELISA. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 45, 46, 47, 48, 49)
- wherein the cell requires L-valine for growth and is capable of growth in at least about 5% oxygen;
-
14. A method of treating a patient having a neurodegenerative condition, the method comprising administering to the patient postpartum-derived cells in an amount effective to treat the neurodegenerative condition, wherein the postpartum-derived cells are derived from human placental or umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
wherein the cells further comprise at least one of the following characteristics;
a) potential for at least about 40 doublings in culture;
b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyomithine, vitronectin, or fibronectin;
c) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin;
d) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
e) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
f) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of a gene encoding;
interleukin 8;
reticulon 1;
chemokine (C—
X—
C motif) ligand 1 (melonoma growth stimulating activity, alpha);
chemokine (C—
X—
C motif) ligand 6 (granulocyte chemotactic protein
2);
chemokine (C—
X—
C motif) ligand 3;
tumor necrosis factor, alpha-induced protein 3;
C-type lectin superfamily member 2;
Wilms tumor 1;
aldehyde dehydrogenase 1 family member A2;
renin;
oxidized low density lipoprotein receptor 1;
Homo sapiens clone IMAGE;
4179671;
protein kinase C zeta;
hypothetical protein DKFZp564F013;
downregulated in ovarian cancer 1; and
Homo sapiens gene from clone DKFZp547k1113.g) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is reduced for at least one of a gene encoding;
short stature homeobox 2;
heat shock 27 kDa protein 2;
chemokine (C—
X—
C motif) ligand 12 (stromal cell-derived factor
1);
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome);
Homo sapiens mRNA;
cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeo box 2 (growth arrest-specific homeo box);
sine oculis homeobox homolog 1 (Drosophila);
crystallin, alpha B;
disheveled associated activator of morphogenesis 2;
DKFZP586B2420 protein;
similar to neuralin 1;
tetranectin (plasminogen binding protein);
src homology three (SH3) and cysteine rich domain;
cholesterol 25-hydroxylase;
runt-related transcription factor 3;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer;
frizzled homolog 7 (Drosophila);
hypothetical gene BC008967;
collagen, type VIII, alpha 1;
tenascin C (hexabrachion);
iroquois homeobox protein 5;
hephaestin;
integrin, beta 8;
synaptic vesicle glycoprotein 2;
neuroblastoma, suppression of tumorigenicity 1;
insulin-like growth factor binding protein 2, 36 kDa;
Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, beta 7;
transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2 (Drosophila);
KIAA1034 protein;
vesicle-associated membrane protein 5 (myobrevin);
EGF-containing fibulin-like extracellular matrix protein 1;
early growth response 3;
distal-less homeo box 5;
hypothetical protein FLJ20373;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan;
transcriptional co-activator with PDZ-binding motif (TAZ);
fibronectin 1;
proenkephalin;
integrin, beta-like 1 (with EGF-like repeat domains);
Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422;
EphA3;
KIAA0367 protein;
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
hypothetical protein FLJ14054;
Homo sapiens mRNA;
cDNA DKFZp564B222 (from clone DKFZp564B222);
BCL2/adenovirus E1B 19 kDa interacting protein 3-like;
AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
similar to neuralin 1;
B cell translocation gene 1;
hypothetical protein FLJ23191; and
DKFZp586L151;
h) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and
i) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIP1b, 1309, MDC, and VEGF, as detected by ELISA. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
-
30. A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and postpartum-derived cells in an effective to treat the neurodegenerative condition wherein the postpartum-derived cells are derived from human placental or umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
wherein the cells further comprise at least one of the following characteristics;
a) potential for at least about 40 doublings in culture;
b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyomithine, vitronectin, or fibronectin;
c) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin;
d) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
e) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
f) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of a gene encoding;
interleukin 8;
reticulon 1;
chemokine (C—
X—
C motif) ligand 1 (melonoma growth stimulating activity, alpha);
chemokine (C—
X—
C motif) ligand 6 (granulocyte chemotactic protein
2);
chemokine (C—
X—
C motif) ligand 3;
tumor necrosis factor, alpha-induced protein 3;
C-type lectin superfamily member 2;
Wilms tumor 1;
aldehyde dehydrogenase 1 family member A2;
renin;
oxidized low density lipoprotein receptor 1;
Homo sapiens clone IMAGE;
4179671;
protein kinase C zeta;
hypothetical protein DKFZp564F013;
downregulated in ovarian cancer 1; and
Homo sapiens gene from clone DKFZp547k1113.g) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is reduced for at least one of a gene encoding;
short stature homeobox 2;
heat shock 27 kDa protein 2;
chemokine (C—
X—
C motif) ligand 12 (stromal cell-derived factor
1);
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome);
Homo sapiens mRNA;
cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeo box 2 (growth arrest-specific homeo box);
sine oculis homeobox homolog 1 (Drosophila);
crystallin, alpha B;
disheveled associated activator of morphogenesis 2;
DKFZP586B2420 protein;
similar to neuralin 1;
tetranectin (plasminogen binding protein);
src homology three (SH3) and cysteine rich domain;
cholesterol 25-hydroxylase;
runt-related transcription factor 3;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer;
frizzled homolog 7 (Drosophila);
hypothetical gene BC008967;
collagen, type VIII, alpha 1;
tenascin C (hexabrachion);
iroquois homeobox protein 5;
hephaestin;
integrin, beta 8;
synaptic vesicle glycoprotein 2;
neuroblastoma, suppression of tumorigenicity 1;
insulin-like growth factor binding protein 2, 36 kDa;
Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, beta 7;
transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2 (Drosophila);
KIAA1034 protein;
vesicle-associated membrane protein 5 (myobrevin);
EGF-containing fibulin-like extracellular matrix protein 1;
early growth response 3;
distal-less homeo box 5;
hypothetical protein FLJ20373;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan;
transcriptional co-activator with PDZ-binding motif (TAZ);
fibronectin 1;
proenkephalin;
integrin, beta-like 1 (with EGF-like repeat domains);
Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422;
EphA3;
KIAA0367 protein;
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
hypothetical protein FLJ14054;
Homo sapiens mRNA;
cDNA DKFZp564B222 (from clone DKFZp564B222);
BCL2/adenovirus E1B 19 kDa interacting protein 3-like;
AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
similar to neuralin 1;
B cell translocation gene 1;
hypothetical protein FLJ23191; and
DKFZp586L151;
h) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and
i) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIPlb, 1309, MDC, and VEGF, as detected by ELISA. - View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
-
41. A kit for treating a patient having a neurodegenerative condition, the kit comprising a pharmaceutically acceptable carrier, a population of postpartum-derived cells and instructions for using the kit in a method of treating the patient, wherein the postpartum-derived cells are derived from human placental or umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
wherein the cells further comprise at least one of the following characteristics;
a) potential for at least about 40 doublings in culture;
b) attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin;
c) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin;
d) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
e) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD 141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
f) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for at least one of a gene encoding;
interleukin 8;
reticulon 1;
chemokine (C—
X—
C motif) ligand 1 (melonoma growth stimulating activity, alpha);
chemokine (C—
X—
C motif) ligand 6 (granulocyte chemotactic protein
2);
chemokine (C—
X—
C motif) ligand 3;
tumor necrosis factor, alpha-induced protein 3;
C-type lectin superfamily member 2;
Wilms tumor 1;
aldehyde dehydrogenase 1 family member A2;
renin;
oxidized low density lipoprotein receptor 1;
Homo sapiens clone IMAGE;
4179671;
protein kinase C zeta;
hypothetical protein DKFZp564F013;
downregulated in ovarian cancer 1; and
Homo sapiens gene from clone DKFZp547k1113.g) expression of a gene, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is reduced for at least one of a gene encoding;
short stature homeobox 2;
heat shock 27 kDa protein 2;
chemokine (C—
X—
C motif) ligand 12 (stromal cell-derived factor
1);
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome);
Homo sapiens mRNA;
cDNA DKFZp586M2022 (from clone DKFZp586M2022);
mesenchyme homeo box 2 (growth arrest-specific homeo box);
sine oculis homeobox homolog 1 (Drosophila);
crystallin, alpha B;
disheveled associated activator of morphogenesis 2;
DKFZP586B2420 protein;
similar to neuralin 1;
tetranectin (plasminogen binding protein);
src homology three (SH3) and cysteine rich domain;
cholesterol 25-hydroxylase;
runt-related transcription factor 3;
interleukin 11 receptor, alpha;
procollagen C-endopeptidase enhancer;
frizzled homolog 7 (Drosophila);
hypothetical gene BC008967;
collagen, type VIII, alpha 1;
tenascin C (hexabrachion);
iroquois homeobox protein 5;
hephaestin;
integrin, beta 8;
synaptic vesicle glycoprotein 2;
neuroblastoma, suppression of tumorigenicity 1;
insulin-like growth factor binding protein 2, 36 kDa;
Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744;
cytokine receptor-like factor 1;
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4;
integrin, beta 7;
transcriptional co-activator with PDZ-binding motif (TAZ);
sine oculis homeobox homolog 2 (Drosophila);
KIAA1034 protein;
vesicle-associated membrane protein 5 (myobrevin);
EGF-containing fibulin-like extracellular matrix protein 1;
early growth response 3;
distal-less homeo box 5;
hypothetical protein FLJ20373;
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II);
biglycan;
transcriptional co-activator with PDZ-binding motif (TAZ);
fibronectin 1;
proenkephalin;
integrin, beta-like 1 (with EGF-like repeat domains);
Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422;
EphA3;
KIAA0367 protein;
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C);
hypothetical protein FLJ14054;
Homo sapiens mRNA;
cDNA DKFZp564B222 (from clone DKFZp564B222);
BCL2/adenovirus E1B 19 kDa interacting protein 3-like;
AE binding protein 1;
cytochrome c oxidase subunit VIIa polypeptide 1 (muscle);
similar to neuralin 1;
B cell translocation gene 1;
hypothetical protein FLJ23191; and
DKFZp586L 151;
h) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and
i) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIP2b, I309, MDC, and VEGF, as detected by ELISA. - View Dependent Claims (42, 43, 44)
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
Specification